Global Gastrointestinal Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Mar-2017
No. of pages: 700
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Summary

The Global Gastrointestinal Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies

Global Gastrointestinal Partnering 2010 to 2017 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Gastrointestinal partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Gastrointestinal partnering agreement structure

Gastrointestinal partnering contract documents

Top Gastrointestinal deals by value

Most active Gastrointestinal dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gastrointestinal deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2010. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.

Report scope

Global Gastrointestinal Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.

Global Gastrointestinal Partnering 2010 to 2017 includes:

Trends in Gastrointestinal dealmaking in the biopharma industry since 2010

Analysis of Gastrointestinal deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Gastrointestinal deal contract documents

Comprehensive access to over 3500 Gastrointestinal deal records

The leading Gastrointestinal deals by value since 2010

Most active Gastrointestinal dealmakers since 2010

The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.

In Global Gastrointestinal Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Gastrointestinal Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 400 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Gastrointestinal Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Gastrointestinal deal trends since 2010

Access Gastrointestinal deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Gastrointestinal partner companies

Comprehensive access to over 750 links to actual Gastrointestinal deals entered into by the world's biopharma companies

Indepth review of Gastrointestinal deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Gastrointestinal opportunities

Uncover companies actively partnering Gastrointestinal opportunities

Global Gastrointestinal Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gastrointestinal dealmaking

2.1. Introduction
2.2. Gastrointestinal partnering over the years
2.3. Gastrointestinal partnering by deal type
2.4. Gastrointestinal partnering by industry sector
2.5. Gastrointestinal partnering by stage of development
2.6. Gastrointestinal partnering by technology type
2.7. Gastrointestinal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Gastrointestinal partnering

3.1. Introduction
3.2. Disclosed financials terms for Gastrointestinal partnering
3.3. Gastrointestinal partnering headline values
3.4. Gastrointestinal deal upfront payments
3.5. Gastrointestinal deal milestone payments
3.6. Gastrointestinal royalty rates

Chapter 4 - Leading Gastrointestinal deals and dealmakers

4.1. Introduction
4.2. Most active in Gastrointestinal partnering
4.3. List of most active dealmakers in Gastrointestinal
4.4. Top Gastrointestinal deals by value

Chapter 5 - Gastrointestinal contract document directory

5.1. Introduction
5.2. Gastrointestinal partnering deals where contract document available

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Gastrointestinal therapeutic target

Appendices

Appendix 1 - Directory of Gastrointestinal deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Gastrointestinal deals by deal type 2010 to 2017
Appendix 3 - Directory of Gastrointestinal deals by stage of development 2010 to 2017
Appendix 4 - Directory of Gastrointestinal deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Gastrointestinal partnering since 2010
Figure 2: Gastrointestinal partnering by deal type since 2010
Figure 3: Gastrointestinal partnering by industry sector since 2010
Figure 4: Gastrointestinal partnering by stage of development since 2010
Figure 5: Gastrointestinal partnering by technology type since 2010
Figure 6: Gastrointestinal partnering by indication since 2010
Figure 7: Gastrointestinal deals with a headline value
Figure 8: Gastrointestinal deals with upfront payment values
Figure 9: Gastrointestinal deals with milestone payment
Figure 10: Gastrointestinal deals with royalty rates
Figure 11: Active Gastrointestinal dealmaking activity- 2010 to 2017
Figure 12: Top Gastrointestinal deals by value since 2010
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 […]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining […]
  • Celiac Disease - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 82
    Celiac Disease - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Ris......
  • Pancreatitis - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 70
    Pancreatitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H1 2017, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape. Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors i......
  • Gastric Ulcers - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 42
    Gastric Ulcers - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H1 2017, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nause......
  • Digestive Remedies Companies in China
    Published: 05-Apr-2017        Price: US 1800 Onwards        Pages: 59
    This study focuses on China's Digestive Remedies industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumption......
  • Digestive Remedies Markets in China
    Published: 05-Apr-2017        Price: US 4000 Onwards        Pages: 218
    China's demand for Digestive Remedies has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, i......
  • Digestive Remedies Industry Forecasts - China Focus
    Published: 05-Apr-2017        Price: US 1800 Onwards        Pages: 113
    This study focuses on China's Digestive Remedies industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services......
  • Global Proglumide Sales Market Report 2017
    Published: 29-Mar-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Proglumide market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (Kg), revenue (Million USD), market share and growth rate of Proglumide for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeast ......
  • EMEA (Europe, Middle East and Africa) Glycopyrrolate (CAS 596-51-0) Market Report 2017
    Published: 29-Mar-2017        Price: US 4000 Onwards        Pages: 102
    In this report, the EMEA Glycopyrrolate (CAS 596-51-0) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Glycopyrrolate (CAS 596-51-0) for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, I......
  • Diabetic Gastroparesis - Pipeline Review, H1 2017
    Published: 22-Mar-2017        Price: US 2000 Onwards        Pages: 57
    Diabetic Gastroparesis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2017, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape. Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs